Vectura Reaps Value From Pan-JAK Inhibitor For Severe Asthma

Kinaset Therapeutics To Evaluate Candidate

The UK’s Vectura plc is gaining value from its back catalog of novel compounds through licensing its pan-JAK inhibitor, VR588, to a US start-up, the venture capital-backed Kinaset Therapeutics.  

hand shake
• Source: Shutterstock

A new US biotech start-up, Kinaset Therapeutics, founded to develop new therapies for asthma, will have as its lead compound a novel pan-JAK inhibitor, KN-002, which is licensed from the UK inhalation specialist company Vectura Group plc and is expected to enter clinical studies in the first half of 2021. 

Not only has Kinaset taken an exclusive global license to KN-002 (formerly Vectura’s VR588), the Medfield, MA-based biotech has also...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Respiratory

More from Therapeutic Category